Comparative efficacy of nonhormonal drugs on menopausal hot flashes
- 912 Downloads
The effects of nonhormonal drugs on menopausal hot flashes are still not well quantified. We therefore did a model-based meta-analysis (MBMA) to quantitate and compare the efficacy features of nonhormonal drugs on menopausal hot flashes.
Literature was searched in the public databases to extract data of clinical trials on nonhormonal drugs, including selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), gabapentin, clonidine, and soy isoflavones. Pharmacodynamic models were used for the quantitative analysis of each drug.
Thirty-nine studies were included in the analysis. The results revealed a classic pharmacodynamic maximal effect (Emax) model could describe the time course of hot-flash reduction by nonhormonal drugs. After deducting placebo effects, the Emax of SSRIs/SNRIs, gabapentin, clonidine, and soy isoflavones was 13.9 %, 14.8 %, 18.5 %, and 25.0 %, respectively. The time to achieve half of the maximal effect (ET50) of SSRIs/SNRIs, gabapentin, clonidine, and soy isoflavones was 0.18 weeks, 0 weeks, 0 weeks, and 11.6 weeks, respectively. The results showed that SSRIs/SNRIs, gabapentin, and clonidine had a rapid onset, which could reach the maximum effect immediately. However, the onset of soy isoflavones was very slow, and a duration of 16.6 weeks was needed to surpass the efficacy of paroxetine (a type of SSRIs).
The information provided in this study can be used as valuable supplementary information for treatment guidelines of nonhormonal drugs on menopausal hot flashes.
KeywordsMenopause Hot flashes Nonhormonal agents Model-based meta-analysis
The authors especially thank Christine M. Derzko (St. Michael’s Hospital, University of Toronto) for valuable contributions to the manuscript. This study was supported by Shanghai Municipal Science and Technology Commission (14CG40, ZY3-CCCX-3-1001) and the Notional Natural Science Funds (81303279).
Compliance with ethical standards
The authors declare that they have no competing interests.
Lujin Li designed the work, analyzed data, and wrote the paper. Ling Xu searched papers and analyzed data. Junyi Wu, Lidan Dong, and Shuiyu Zhao contributed to data extraction and cleaning. Qingshan Zheng participated in conception and design of the work and revised the paper critically for important intellectual content.
- 1.(2015) Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 22(11):1155–1174Google Scholar
- 7.Boucher M, Bennetts M (2016) The Many Flavors of Model-Based Meta-Analysis: Part I—Introduction and Landmark Data. CPT: Pharmacometrics Syst Pharmacol 5(2):54–64Google Scholar
- 8.Mandema JW, Salinger DH, Baumgartner SW (2011) A Dose–Response Meta-Analysis for Quantifying Relative Efficacy of Biologics in Rheumatoid Arthritis Clinical Pharmacology & Therapeutics 90(6):828–835Google Scholar
- 13.(2003) Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms –recommendations for clinical evaluation. FDAGoogle Scholar
- 16.(2015) Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 22(11):1155–1172Google Scholar